Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

PVI/MM/Seronet Study Group

doi:10.1016/j.ccell.2022.03.013

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

PVI/MM/Seronet Study Group

Research output: Contribution to journal › Letter › peer-review

33 Scopus citations

Original language	English
Pages (from-to)	441-443
Number of pages	3
Journal	Cancer Cell
Volume	40
Issue number	5
DOIs	https://doi.org/10.1016/j.ccell.2022.03.013
State	Published - 9 May 2022

Access to Document

10.1016/j.ccell.2022.03.013

Cite this

@article{61c694d0609647cb94a9e532f477373a,

title = "Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients",

author = "{PVI/MM/Seronet Study Group} and Adolfo Aleman and {Van Oekelen}, Oliver and Bhaskar Upadhyaya and Katherine Beach and {Kogan Zajdman}, Ariel and Hala Alshammary and Kseniya Serebryakova and Sarita Agte and Katerina Kappes and Gleason, {Charles R.} and Komal Srivastava and D. Andre and A. Azad and R. Banu and Berm{\'u}dez-Gonz{\'a}lez, {M. C.} and G. Cai and A. Chari and H. Cho and C. Cognigni and K. David and D. Floda and A. Firpo and G. Kleiner and N. Lyttle and W. Mendez and Mulder, {L. C.F.} and R. Mendu and A. Oostenink and A. Rooker and S. Richard and J. Richter and C. Rodriguez and A. Rossi and K. Russo and L. Sanchez and A. Salimbangon and M. Saksena and A. Shin and L. Sominsky and D. Verina and Steve Almo and Carlos Cordon-Cardo and Florian Krammer and Miriam Merad and Sundar Jagannath and Ania Wajnberg and Viviana Simon and Samir Parekh",

note = "Funding Information: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Carlos Cardon-Cordo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Ajai Chari reports grants and personal fees from Janssen , Bristol Myers Squibb (Celgene), Amgen , Seattle Genetics , and Millennium Pharmaceuticals / Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm , and Amgen . The other authors reported no relevant conflicts of interest. Funding Information: We thank participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. None of this work would be possible without their contributions. We acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai. S.P. is supported by National Cancer Institute (NCI) R01 CA244899, CA252222 and receives research funding from Amgen, Celgene/BMS, and Karyopharm. This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS, contracts HHSN272201400008C and HHSN272201400006C), and NIAID grants U01AI141990 and U01AI150747; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 [5384]); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract 75N91019D00024, task order 75N91021F00001. This work was supported by The Price Family Foundation (SCA), the Wollowick Family Foundation Chair in Multiple Sclerosis and Immunology (SCA), the Einstein-Rockefeller-CUNY Center for AIDS Research (P30AI124414), and the Einstein Macromolecular Therapeutics Development Facility supported by the Albert Einstein Cancer Center (P30CA013330). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. We acknowledge support of the Center of Excellence for Multiple Myeloma Philantropy. V.S. A.W. S.P. and PVI study group provided conceptualization, methodology, analysis, and resources for this work. A.A. O.V.O. K.K. K.B. K. Serebryakova, S.A. C.R.G. K. Srivastava, and PVI were involved in organizational aspects of the clinical studies, patient recruitment, data collection, and analysis. A.A. O.V.O. S.A. C.R.G. C.C.-C. and F.K. were involved in design, data collection, analysis, visualization, and interpretation of serological data. A.A. B.U. K.T. and A.K.Z. were involved in design, execution, analysis, visualization, and interpretation of T and B and T cell assays. S.J. A.W. S.P. V.S. and MM Clinical Group were involved in different aspects of patient care. A.A. O.V.O. B.U. M.M. S.J. A.W. V.S. and S.P. provided interpretation of the data and conceptualization of the first manuscript draft. A.A. O.V.O. B.U. A.W. V.S. and S.P. contributed to the writing of the first manuscript draft. H.A. V.S. C.R.G. K. Srivastava, K.B. and PVI study group were involved in neutralization assays and serological quantification. The Almo lab made recombinant spike protein used in spike-reactive B cell identification. All coauthors provided critical edits to the initial manuscript draft and approved the final version. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Carlos Cardon-Cordo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Ajai Chari reports grants and personal fees from Janssen, Bristol Myers Squibb (Celgene), Amgen, Seattle Genetics, and Millennium Pharmaceuticals/Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen. The other authors reported no relevant conflicts of interest.",

year = "2022",

month = may,

day = "9",

doi = "10.1016/j.ccell.2022.03.013",

language = "English",

volume = "40",

pages = "441--443",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

AU - PVI/MM/Seronet Study Group

AU - Aleman, Adolfo

AU - Van Oekelen, Oliver

AU - Upadhyaya, Bhaskar

AU - Beach, Katherine

AU - Kogan Zajdman, Ariel

AU - Alshammary, Hala

AU - Serebryakova, Kseniya

AU - Agte, Sarita

AU - Kappes, Katerina

AU - Gleason, Charles R.

AU - Srivastava, Komal

AU - Andre, D.

AU - Azad, A.

AU - Banu, R.

AU - Bermúdez-González, M. C.

AU - Cai, G.

AU - Chari, A.

AU - Cho, H.

AU - Cognigni, C.

AU - David, K.

AU - Floda, D.

AU - Firpo, A.

AU - Kleiner, G.

AU - Lyttle, N.

AU - Mendez, W.

AU - Mulder, L. C.F.

AU - Mendu, R.

AU - Oostenink, A.

AU - Rooker, A.

AU - Richard, S.

AU - Richter, J.

AU - Rodriguez, C.

AU - Rossi, A.

AU - Russo, K.

AU - Sanchez, L.

AU - Salimbangon, A.

AU - Saksena, M.

AU - Shin, A.

AU - Sominsky, L.

AU - Verina, D.

AU - Almo, Steve

AU - Cordon-Cardo, Carlos

AU - Krammer, Florian

AU - Merad, Miriam

AU - Jagannath, Sundar

AU - Wajnberg, Ania

AU - Simon, Viviana

AU - Parekh, Samir

N1 - Funding Information: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Carlos Cardon-Cordo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Ajai Chari reports grants and personal fees from Janssen , Bristol Myers Squibb (Celgene), Amgen , Seattle Genetics , and Millennium Pharmaceuticals / Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm , and Amgen . The other authors reported no relevant conflicts of interest. Funding Information: We thank participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. None of this work would be possible without their contributions. We acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai. S.P. is supported by National Cancer Institute (NCI) R01 CA244899, CA252222 and receives research funding from Amgen, Celgene/BMS, and Karyopharm. This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS, contracts HHSN272201400008C and HHSN272201400006C), and NIAID grants U01AI141990 and U01AI150747; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 [5384]); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract 75N91019D00024, task order 75N91021F00001. This work was supported by The Price Family Foundation (SCA), the Wollowick Family Foundation Chair in Multiple Sclerosis and Immunology (SCA), the Einstein-Rockefeller-CUNY Center for AIDS Research (P30AI124414), and the Einstein Macromolecular Therapeutics Development Facility supported by the Albert Einstein Cancer Center (P30CA013330). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. We acknowledge support of the Center of Excellence for Multiple Myeloma Philantropy. V.S. A.W. S.P. and PVI study group provided conceptualization, methodology, analysis, and resources for this work. A.A. O.V.O. K.K. K.B. K. Serebryakova, S.A. C.R.G. K. Srivastava, and PVI were involved in organizational aspects of the clinical studies, patient recruitment, data collection, and analysis. A.A. O.V.O. S.A. C.R.G. C.C.-C. and F.K. were involved in design, data collection, analysis, visualization, and interpretation of serological data. A.A. B.U. K.T. and A.K.Z. were involved in design, execution, analysis, visualization, and interpretation of T and B and T cell assays. S.J. A.W. S.P. V.S. and MM Clinical Group were involved in different aspects of patient care. A.A. O.V.O. B.U. M.M. S.J. A.W. V.S. and S.P. provided interpretation of the data and conceptualization of the first manuscript draft. A.A. O.V.O. B.U. A.W. V.S. and S.P. contributed to the writing of the first manuscript draft. H.A. V.S. C.R.G. K. Srivastava, K.B. and PVI study group were involved in neutralization assays and serological quantification. The Almo lab made recombinant spike protein used in spike-reactive B cell identification. All coauthors provided critical edits to the initial manuscript draft and approved the final version. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Carlos Cardon-Cordo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Ajai Chari reports grants and personal fees from Janssen, Bristol Myers Squibb (Celgene), Amgen, Seattle Genetics, and Millennium Pharmaceuticals/Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen. The other authors reported no relevant conflicts of interest.

PY - 2022/5/9

Y1 - 2022/5/9

UR - http://www.scopus.com/inward/record.url?scp=85129385698&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2022.03.013

DO - 10.1016/j.ccell.2022.03.013

M3 - Letter

C2 - 35390296

AN - SCOPUS:85129385698

SN - 1535-6108

VL - 40

SP - 441

EP - 443

JO - Cancer Cell

JF - Cancer Cell

IS - 5

ER -